Core Viewpoint - ICON Public Limited Company is currently facing scrutiny due to an investigation into its accounting practices, which has significantly impacted its stock price and raised concerns among investors [2][3][6] Financial Performance - ICON is scheduled to release its quarterly earnings on March 18, 2026, with analysts estimating earnings per share (EPS) of $3.24 and projected revenue of approximately $2 billion [2][6] - Prior to the investigation, ICON's stock was trading confidently, with expected full-year revenue between $8.05 billion and $8.1 billion and adjusted EPS guidance of $13.00 to $13.20 [4] Stock Price Impact - Following the announcement of the internal investigation, ICON's stock price dropped by $53.06 per share, marking a 39.85% decrease and closing at $80.08 per share [3][4] - This decline erased billions in shareholder value and represents one of the largest percentage drops in the CRO sector in recent years [4] Valuation Metrics - Despite the ongoing challenges, ICON's financial metrics indicate a price-to-earnings (P/E) ratio of approximately 13.10 and a price-to-sales ratio of about 0.96, suggesting efficient conversion of operating cash flow into enterprise value [5][6] - The enterprise value to sales ratio is around 1.34, and the enterprise value to operating cash flow ratio is approximately 9.22 [5]

NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating ICON PLC (“ICON” or the “Company”) (NASDAQ: ICLR) for potential violations of the federal securities laws. On February 12, 2026, ICON issued a press release entitled "ICON plc Provides Update on Timing of Fourth Quarter and Full Year 2025 Earnings Results and Investigation into Accounting Practices." The release stated that ICON "intends to release its ...

Core Viewpoint - ICON Public Limited Company is under investigation for potential violations of federal securities laws, following a significant decline in shareholder value due to a revenue overstatement and a delay in financial results [1][2]. Group 1: Financial Performance and Market Reaction - The recent single-day decline in ICON's stock wiped out billions of dollars in shareholder value, marking one of the largest percentage drops in the Contract Research Organization (CRO) sector in recent years [2]. - Prior to the disclosure, ICON's stock traded within a range that reflected investor confidence, with analyst consensus estimating full-year 2025 revenue between $8.05 billion and $8.1 billion, and adjusted EPS guidance of $13.00 to $13.20 [2]. - The company disclosed a preliminary revenue overstatement of under two percent per year for fiscal years 2023 and 2024, which led to the delay in releasing Q4 and full-year 2025 results [3]. Group 2: Management Statements and Stock Buybacks - CEO Barry Balfe had previously indicated that the company's performance was "broadly in line with expectations," while CFO Nigel Clerkin reported Q3 2025 revenue of $2.043 billion, reflecting a year-over-year increase of 0.6 percent [3]. - In the quarters leading up to the disclosure, ICON repurchased $750 million of its own stock and had a new $1 billion buyback authorization approved, indicating management's confidence in the company's financial position [4]. - A filing on January 7, 2026, stated that full-year 2026 guidance would be issued alongside the delayed Q4 and full-year 2025 results, which has now been rendered moot [4].

327,360-$7.033.60%$188.00Constellation EnergyCEG• Vol: 606,615-$11.273.55%$305.82 of around 20x and a consensus target of $163.29 already well above current levels, Citi's $185 target represents meaningful additional conviction. The Biocare deal adds a growth-oriented pathology platform that CEO Padraig McDonnell described as competing directly against Danaher's Leica unit and Roche's Ventana division in a segment growing at mid-to-high single digits.For Icon, the target cut from $200 to $120 is a structura ...

Group 1 - Polen Capital's fourth-quarter 2025 investor letter indicates a challenging environment for its quality-heavy portfolio, which returned -2.5% gross of fees, lagging behind the MSCI All Country World Index's 3.3% gain [1] - The stock market experienced a significant 5% sell-off in Q4 2025 but quickly rebounded to all-time highs, reflecting a V-shaped recovery similar to that seen from April lows [1] - The portfolio's software holdings underperformed despite revenue and earnings growth, contributing to the overall performance headwinds faced by the Fund [1] Group 2 - ICON Public Limited Company (NASDAQ:ICLR) is highlighted as a stock in the Polen Global Growth Strategy, with a market capitalization of $8.56 billion [2] - The stock of ICON Public Limited Company closed at $110.03 per share on March 09, 2026, with a one-month return of -23.88% and a 52-week loss of 37.40% [2] - Polen Global Growth Strategy decided to exit its position in ICON Public Limited Company due to short to intermediate-term growth challenges, reallocating to opportunities with stronger business momentum [3] Group 3 - ICON Public Limited Company is not among the 40 most popular stocks among hedge funds heading into 2026, with 41 hedge fund portfolios holding the stock at the end of Q4, down from 43 in the previous quarter [4] - While acknowledging ICON's potential, the strategy suggests that certain AI stocks may offer greater upside potential and less downside risk [4]

Core Viewpoint - ICON Public Limited Company (NASDAQ:ICLR) is currently viewed as a compelling investment opportunity despite ongoing internal accounting investigations and recent stock price adjustments by analysts [2][3]. Group 1: Analyst Upgrades - Jefferies analyst David Windley upgraded ICON from Hold to Buy, lowering the price target from $175 to $135, citing the stock's current valuation as "hard to ignore" [2]. - TD Cowen analyst Charles Rhyee also upgraded ICON from Hold to Buy, with a revised price target of $120, down from $183, suggesting that the recent selloff related to the internal accounting investigation is overdone [3]. Group 2: Internal Investigation - ICON disclosed an internal investigation initiated by the Audit Committee in October 2025, focusing on revenue recognition practices from fiscal years 2023 to 2025 [4]. - Preliminary findings suggest that revenue for 2023 and 2024 may have been overstated by less than 2% for each year, and the company expects to report one or more material weaknesses in internal controls [4]. Group 3: Company Overview - ICON provides outsourced development and commercialization services to pharmaceutical, biotechnology, and medical device companies globally [5].

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of ICON plc regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Company Investigation - ICON plc announced an ongoing internal investigation into its accounting practices and controls, initiated by the Audit Committee of the Board of Directors in late October 2025 [3]. - The company plans to release its fourth quarter and full year 2025 earnings results on or prior to April 30, 2026 [3]. Group 2: Stock Price Impact - Following the announcement of the internal investigation, ICON's stock price fell by $53.06 per share, representing a decline of 39.85%, closing at $80.08 per share on February 12, 2026 [3].

Core Viewpoint - ICON Public Limited Company is under investigation for potential violations of federal securities laws, following a significant decline in shareholder value due to a revenue overstatement and delayed earnings release [1][2]. Financial Performance and Market Reaction - The company's single-day stock decline resulted in the loss of billions of dollars in shareholder value, marking one of the largest percentage drops in the Contract Research Organization (CRO) sector in recent years [2]. - Prior to the disclosure, ICON's stock reflected investor confidence, with a full-year 2025 revenue guidance of $8.05 billion to $8.1 billion and adjusted EPS guidance of $13.00 to $13.20, affirmed by management on October 23, 2025 [2][3]. - The company identified a preliminary revenue overstatement of under two percent for fiscal years 2023 and 2024, which contributed to the abrupt sell-off [3]. Management Statements and Financial Actions - CEO Barry Balfe had previously indicated that the company's performance was "broadly in line with expectations," while CFO Nigel Clerkin reported Q3 2025 revenue of $2.043 billion, reflecting a year-over-year increase of 0.6 percent [3]. - In the quarters leading up to the disclosure, ICON repurchased $750 million of its own stock and had a new $1 billion buyback authorization, indicating prior confidence in its financial position [4]. Guidance and Future Outlook - A filing on January 7, 2026, indicated that full-year 2026 guidance would be released alongside the delayed Q4 and full-year 2025 results, which has now been rendered moot due to the delay announcement [4].

ICON Public Limited Company (NASDAQ:ICLR) is one of the most undervalued AI stocks to buy now. With significant analyst and hedge fund sentiment, alongside a low forward price-to-earnings (PE) ratio, ICON Public Limited Company (NASDAQ:ICLR) secures a spot on our list of the most undervalued AI stocks to buy now. Amid an internal accounting investigation, the stock has slid nearly 50% and 45% on a one-year and year-to-date basis, respectively. Analysts at Jefferies revisited the stock on February 23, 20 ...

Core Viewpoint - ICON Public Limited Company is facing internal scrutiny regarding accounting practices related to revenue recognition, leading to a delay in its financial results for Q4 and full-year 2025 [1][2] Financial Results and Guidance - The company plans to release its delayed financial results on or before April 30, 2026, and has withdrawn its previously issued full-year 2025 financial guidance due to an ongoing investigation by the Audit Committee [2] - Analysts had previously estimated Q4 2025 adjusted EPS to be between $3.27 and $3.32, with revenue expected around $2.00 to $2.01 billion, reflecting modest year-over-year declines [3] - Full-year 2025 consensus estimates for adjusted EPS were in the range of $12.99 to $13.03, with revenue expected between $8.05 and $8.11 billion, down from prior guidance [3] Market Reaction - Following the announcement of the delay and guidance withdrawal, ICON's shares experienced a significant sell-off, dropping approximately 30-40% and reaching multi-year lows in the $70-$90 range [3] Legal Investigations - Multiple law firms have initiated investigations into potential securities law violations, with alerts issued for investors who purchased shares prior to the news [4] Industry Context - ICON operates in the contract research organization (CRO) sector, providing clinical development services to pharmaceutical and biotechnology companies, and competes with firms like IQVIA and Labcorp [4] - The CRO industry relies heavily on accurate revenue recognition for long-term contracts, making the current issues particularly sensitive [4] Financial Metrics - The earnings yield has increased to around 7-8% or higher following the drop in share price, indicating significant uncertainty priced into the market valuation [5] - Trailing P/E ratio is approximately 13-20x, with a price-to-sales ratio around 1.6-1.9x, and enterprise value to sales at approximately 1.3-2.0x [7] - The debt-to-equity ratio stands at 0.38, indicating moderate leverage, while the current ratio is 1.06, suggesting adequate short-term liquidity [7] Future Outlook - The ongoing investigation and delay highlight risks in financial reporting for CROs, with investors awaiting clarity on restated prior periods and updated outlooks for 2025 and 2026 [6]